Fracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase

Adrian Martinez de la Torre, Andreas Bech Clausen, Andrea M. Burden and Stefan Weiler ()
Additional contact information
Adrian Martinez de la Torre: Swiss Federal Institute of Technology Zurich ETH Zürich
Andreas Bech Clausen: Swiss Federal Institute of Technology Zurich ETH Zürich
Andrea M. Burden: Swiss Federal Institute of Technology Zurich ETH Zürich
Stefan Weiler: Swiss Federal Institute of Technology Zurich ETH Zürich

Drug Safety, 2025, vol. 48, issue 2, No 8, 201 pages

Abstract: Abstract Introduction The Janus kinase (JAK) inhibitors are treatment options for autoimmune diseases. Numerous safety concerns have been raised. The European Medicines Agency updated the product information of tofacitinib to include the risk of fractures—but not for other JAK inhibitors. We conducted a global pharmacovigilance analysis of previously investigated JAK inhibitors to investigate a potential class effect. Methods Individual case safety reports (ICSRs) for all licensed JAK inhibitors were identified from the global WHO pharmacovigilance database. The primary outcome of interest was a bone fracture. Disproportionality analyses using reporting odds ratios (RORs) were conducted. Results We identified 122,037 ICSRs for tofacitinib, 27,786 ICSRs for upadacitinib, 14,616 ICSRs for baricitinib, 830 for filgotinib, and 350 for abrocitinib. Among the ICSRs, we identified 2198 (1.8%), 634 (2.3%), and 144 (1.0%) reports, where a bone fracture was reported for tofacitinib, upadacitinib, and baricitinib, respectively. Few reports were available for the newest drugs filgotinib (10) and abrocitinib (1). JAK inhibitors were associated with increased reporting for fracture: tofacitinib (ROR 3.34, 95% confidence interval [CI] 3.20–3.48), upadacitinib (ROR 4.23, 95% CI 3.80–4.48), baricitinib (ROR 1.80, 95% CI 1.52–2.11) and filgotinib (ROR 2.24, 95% CI 1.11–3.94). Patients with bone fractures were more often female, older and had a higher number of co-reported medications. They were more likely to use glucocorticoids, opioids, and bisphosphonates. Conclusion The results from this pharmacovigilance analysis, based on a spontaneous reporting database associated with inherent limitations, suggest a potential risk of fractures with JAK inhibitors, indicating that a class effect cannot be ruled out.

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-024-01490-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:48:y:2025:i:2:d:10.1007_s40264-024-01490-w

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-024-01490-w

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().